GlobalData on MSN21h
Pfizer’s Talzenna gains 14-months OS lead over mCRPC SoCResults from the company’s Talapro-2 trial saw a 38% reduction in the risk of death among HRR-mutated patients.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback